CNTA · Centessa Pharmaceuticals plc · Stock research

Current Thesis

The special situation closed by consummation and the listed instrument no longer exists; what remains is a contingent-value question that cannot be expressed in this symbol. Eli Lilly's UK scheme of arrangement — $38.00 cash per share plus one non-transferable contingent value right of up to $9.00 — became effective 2026-06-24 through LDH XV Corporation after High Court sanction on 2026-06-22 (CNTA Form 8-K, 2026-06-24). The final Nasdaq ADS session was 2026-06-23; the Form 15-12G deregistering the ADSs is dated 2026-07-06.

One thing has advanced since the prior note. ClinicalTrials.gov carries NCT07598708, "A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence," listed as Phase 2/Phase 3, Recruiting, start date 2026-05-29, primary completion 2027-09-30, sponsored by Centessa Pharmaceuticals (UK) Limited (registry record retrieved 2026-08-23). That sits alongside Lilly's own second-quarter release of 2026-08-05, which still described cleminorexton (formerly ORX750) as having shown a potential best-in-class profile in Phase 2a studies. The registry field is sponsor-entered and revisable, so it is a dated indication of program stage, not a company statement of registrational start. That distinction is the entire live question for CVR milestone timing — and the CVR pays scheme record holders.

Bullish and bearish views on Centessa Pharmaceuticals plc

The model's bull view on Centessa Pharmaceuticals plc (CNTA), in brief: Consideration cleared with no re-cut. Sanction 2026-06-22, effective 2026-06-24, $38.00 cash fixed (Form 8-K, 2026-06-24). Announcement day 2026-03-31 produced a ~45% single-session move on headline value around $7.8B and roughly a 40% premium (Benzinga, 2026-03-31 /… The bear view: There is no security to own. Delisted 2026-06-24; Form 15-12G dated 2026-07-06. Any CNTA quote a vendor still renders is the 2026-06-23 print on a dormant feed. The CVR is non-transferable. It went to scheme record holders under the CVR Agreement (proxy Annex B) and cannot be… Both cases follow in full.

Bull Case

• Consideration cleared with no re-cut. Sanction 2026-06-22, effective 2026-06-24, $38.00 cash fixed (Form 8-K, 2026-06-24). Announcement day 2026-03-31 produced a ~45% single-session move on headline value around $7.8B and roughly a 40% premium (Benzinga, 2026-03-31 / 2026-04-01).
• Registry stage now runs ahead of the press language. NCT07598708 is listed Phase 2/Phase 3 and recruiting since 2026-05-29, with primary completion 2027-09-30 — the first dated public marker of work beyond a pure 2a design (ClinicalTrials.gov, retrieved 2026-08-23).
• The predecessor study is still generating data. NCT06752668 ("A Study of ORX750 in Participants With Narcolepsy and Idiopathic Hypersomnia"), Phase 2, start 2024-12-23, remains listed as recruiting with a December 2026 primary completion.
• The asset survived its first reporting cycle inside the acquirer. Lilly's 2026-08-05 release names Centessa under completed Q2 business development and names cleminorexton, rather than folding it into an unnamed neuroscience line. Lilly reported Q2 revenue of $23.0B, +48% year over year, and raised FY2026 guidance to $85.0–87.0B in the same release.
• The CVR perimeter is wider than one molecule. The merger proxy names cleminorexton, ORX142 and ORX489 (DEFM14A filed 2026-05-07; PREM14A 2026-04-17).
• The mechanism has cleared a US review. FDA approved Takeda's ORZEYFUL (oveporexton), an oral OX2R agonist, for NT1 on 2026-08-05 on two randomized double-blind placebo-controlled Phase 3 trials enrolling 273 adults.

Bear Case

• There is no security to own. Delisted 2026-06-24; Form 15-12G dated 2026-07-06. Any CNTA quote a vendor still renders is the 2026-06-23 print on a dormant feed.
• The CVR is non-transferable. It went to scheme record holders under the CVR Agreement (proxy Annex B) and cannot be bought, sold or hedged. A favourable cleminorexton outcome produces no move in this symbol under any scenario.
• Milestone terms are not observable at the level that matters. The aggregate is capped at $9.00 per share; the individual triggers and dates are not disclosed in a form that lets an outsider mark progress against them.
• The clock is long. Primary completion on NCT07598708 is 2027-09-30. Even on the registry's own dates, resolution of the registrational question sits well past 2026.
• The follower problem hardened on 2026-08-05. ORZEYFUL is approved in NT1. Alkermes announced initiation of the Phase 3 Brilliance program on 2026-04-01 — three 12-week randomized, double-blind, placebo-controlled studies (302 and 304 in NT1, 303 in NT2) of alixorexton.
• Sell-side marks are frozen artefacts. Needham. Nothing has been revised since 2026-04-20 because there is nothing to rate.

Setup & Price Structure

The narrative is dead — structure broken by delisting, dated by the last tradable session on 2026-06-23, the 2026-06-24 effectiveness of the scheme, and the 2026-07-06 Form 15-12G. The orexin narrative itself is alive and accelerating; it simply no longer has this ticker as a vehicle.

The tape is frozen at one session. The 2026-06-23 adjusted close of $40.50 is also the 52-week high — the name screens 0.0% below it — with RSI(14) at 71.1 and a three-month price change of +45.2%, all fixed at that print. No session has occurred since; the vendor timestamp does not advance.

Crowding and positioning observables, stated as observables: a momentum screen run today returns a name at its 52-week high with a 71-handle RSI and zero subsequent volume, which is a data artefact of the halt rather than participation. The pre-vote register into the 2026-06-12 scheme meeting was institutional-heavy — Samlyn, Bain and Perceptive appear in the pre-close 13F record — and the June tape was deal arbitrage rather than retail-squeeze mechanics. There is no upcoming earnings date, no analyst revision flow since 2026-04-20, and no possibility of insider Form 4 activity: Section 16 duties ended with deregistration. Issuance into strength is likewise impossible.

Catalyst Calendar (next 30 days)

• 2026-08-23 → 2026-09-22: no dated company event falls in the window. No earnings date, no filing deadline, no listing on which a print can occur.
• ~2026-10-04 (est.): termination of ADS registration on the standard 90-day path from the 2026-07-06 Form 15-12G — the last public-disclosure channel on the entity closes.
• ~2026-10-29 (est.): Lilly third-quarter 2026 results and pipeline update — the first scheduled disclosure where a cleminorexton registrational start, or a demotion, would surface.
• ~December 2026 (est., per registry): primary completion listed for NCT06752668, the Phase 2 ORX750 study.
• 2027-09-30 (registry-listed): primary completion for NCT07598708, the Phase 2/Phase 3 cleminorexton study.

What Would Change Our Mind

The structural facts, not the price, are what would have to move. Two conditions would reopen this symbol as a market object: a relisting of an entity that has already filed to stop Exchange Act reporting, or a change to the CVR's non-transferability creating a tradable claim. Neither has a filed path as of 2026-08-23, and the 90-day deregistration clock running to ~2026-10-04 points the other way.

On the CVR itself, the read changes on: NCT07598708 flipping from Recruiting to Suspended, Withdrawn or Terminated, or its phase field being revised down; cleminorexton being absent from or demoted in Lilly's Q3 pipeline table at the ~2026-10-29 release; or, in the other direction, an explicit Lilly statement of a registrational start, which would be the first company-sourced confirmation that the registry entry reflects a Phase 3 commitment.

For grading purposes, the price condition that would break a long thesis here is a daily close below $38.00 — the scheme's cash consideration — and it cannot print, because no session has occurred since 2026-06-23 and none will.

Correlation Notes

• Read-through from cleminorexton now expresses in LLY (acquirer; at $23.0B of Q2 revenue, the asset is immaterial to the parent's price), Takeda (ORZEYFUL approved 2026-08-05, the NT1 first-mover) and ALKS (alixorexton, Brilliance Phase 3 initiated per the 2026-04-01 announcement). Orexin-class sentiment moves those, never this symbol.
• Takeout-beta correlation ended on 2026-06-23. On the 2026-03-31 announcement tape, CNTA moved alongside Apellis, which was +136.4% on a Biogen buyout at $41/share — a same-session biotech M&A cluster. CNTA no longer contributes covariance to anything; the series is a constant.
• For anyone running a screen or backtest across this window, the frozen $40.50 print will behave as a live near-high observation and will bias any momentum or breadth statistic that includes it.